Brenntag

Brenntag shares fell about 1.7% to €60.09, triggered by a sector-wide sell-off after Morgan Stanley downgraded Evonik. The InvestingPro fair-value model values the stock at €66.72 (≈+10.9%), while the analyst consensus with an average target of €57.73 remains neutral. Operationally Brenntag delivered a strong Q2 (EBITDA €463m) and confirmed the annual target of around €1.45bn, but warned of waning price tailwinds. The key date will be 11 November, when Q3 figures will show whether the EBITDA target holds despite the headwinds. » Más en de.investing.com

Brenntag has successfully placed a €500 million bond with a seven-year maturity and a 4.25% coupon at a price of 99.626%. The proceeds are for general corporate purposes and are intended to secure financial flexibility for strategic and operational goals. The transaction extends the maturity profile of the liabilities, and the stock reacted slightly positively intraday. » Más en finanzen.net

UBS analyst Nicole Manion has raised Brenntag’s price target from 60 to 61 euros but kept the rating at neutral. Inflationary chemical prices and supply-chain disruptions from the Middle East conflict have helped in the short term, yet upside is limited as the price boost is expected to fade in the second half of the year. Brenntag shares are up 27.5 percent year-to-date 2026; Q3 figures are expected on November 11, 2026. » Más en finanzen.net